"The bottom line in 2007 is that enrollment costs are going up substantially, drug coverage is declining and the brand name coverage in the doughnut hole is being eliminated... Medicare D is an insurance program, not a benefit. As consumption increases, so too will cost. The changes in 2007 clearly demonstrate the limitations of the program."

Previous Quote

Pharmacogenomics holds great promise to shed scientific light on the often risky and costly process of drug development, and to provide greater confidence about the risks and benefits of drugs in specific populations. Pharmacogenomics is a new field, but we intend to do all we can to use it to promote the development of medicines. By providing practical guidance on how to turn the explosion of pharmacogenomic information into real evidence on new drugs, we are taking an important step toward that goal.

— Mark McClellan